Expanding the triglyceride range in clinical trials: therapeutic opportunities
Authors' conclusion
Individuals with mild-to-moderate hypertriglyceridaemia may not express the same magnitude of cardiovascular risk as that observed across the full range of plasma triglycerides.
Study context
- Population
- Individuals with baseline TG 2.3–5.6 mmol/L (Copenhagen General Population Study, Women's Health Study) and mild-to-moderate hypertriglyceridaemia (PROMINENT, REDUCE-IT, STRENGTH trials); plus full-range TG cohort
- Comparison
- Baseline triglyceride quartiles
- Outcome
- Major CV events and death by baseline TG
Methodological detailsmultivariable-adjusted
- Multivariable-adjusted
Pooled result
As reported in the abstract
Major CV events by TG quartile
Hazard ratio (95% CI)
Q2 vs Q1cohorts
0.95(0.87–1.04)
Q3 vs Q1cohorts
1.04(0.95–1.13)
Q4 vs Q1cohorts
1.13(1.04–1.23)
Q2 vs Q1trials
1.01(0.93–1.10)
Q3 vs Q1trials
1.05(0.96–1.14)
Q4 vs Q1trials
1.09(1.00–1.19)
Further pooled results
Major CV events across full TG range (0.3 to 11.2 mmol/L)
- Increasing TG associated with increasing risk of major CV events
- 119 573 individuals, Copenhagen General Population Study; N = 12 241 events
CV and all-cause death
- In neither cohorts nor trials were TG across this range strongly associated with CV or all-cause death
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Expanding the triglyceride range in clinical trials: therapeutic opportunities. Eur Heart J. Published 14 February 2025. doi:10.
Summarised from the published abstract; every number is checked against it